The impact of thromboprophylaxis with LMWHs on the survival of patients with pancreatic cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The impact of thromboprophylaxis with LMWHs on the survival of patients with pancreatic cancer
Authors
Keywords
Pancreatic cancer, Venous thromboembolism, Low molecular weight heparins, Thromboprophylaxis
Journal
THROMBOSIS RESEARCH
Volume 213, Issue -, Pages S120-S126
Publisher
Elsevier BV
Online
2022-05-26
DOI
10.1016/j.thromres.2022.02.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
- (2021) Gary H. Lyman et al. Blood Advances
- Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer
- (2021) Panagiotis Sarantis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice
- (2021) Roberta Roberti et al. Frontiers in Pharmacology
- The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study
- (2021) Michalis V. Karamouzis et al. Cancers
- Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas
- (2020) Alexandros Bokas et al. Cancers
- Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
- (2020) Panagiotis Sarantis et al. World Journal of Gastrointestinal Oncology
- Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented
- (2020) Dominique Farge et al. Cancers
- Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?
- (2020) Nikolaos Tsoukalas et al. Cancers
- Progress in the study of cancer-associated venous thromboembolism
- (2020) Yuting Yao et al. Vascular
- Update on Guidelines for the Management of Cancer‐Associated Thrombosis
- (2020) Michael B. Streiff et al. ONCOLOGIST
- Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications
- (2019) Yilan Ouyang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study
- (2019) Harry J. M. Groen et al. BRITISH JOURNAL OF CANCER
- Cancer treatment and survivorship statistics, 2019
- (2019) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The non-anticoagulant promise of heparin and its mimetics
- (2019) Barbara Mulloy CURRENT OPINION IN PHARMACOLOGY
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2019) Nigel S. Key et al. JOURNAL OF CLINICAL ONCOLOGY
- 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
- (2019) Dominique Farge et al. LANCET ONCOLOGY
- Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes
- (2019) Corinne Frere et al. GASTROENTEROLOGY
- Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis
- (2018) Ang Li et al. THROMBOSIS RESEARCH
- Antitumor Effect of Low Molecular Weight Heparin in Localised Lung Cancer A Phase III Clinical Trial
- (2018) Guy Meyer et al. EUROPEAN RESPIRATORY JOURNAL
- High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study
- (2017) Anne Katrin Berger et al. PANCREATOLOGY
- Tumor-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival
- (2017) Ke-Xing Xi et al. Journal of Thoracic Disease
- nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
- (2016) Mustapha Tehfe et al. ADVANCES IN THERAPY
- Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells
- (2015) Daniel Bastian Pfankuchen et al. BIOCHEMICAL PHARMACOLOGY
- Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer
- (2015) Agnes Y. Y. Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
- (2015) Uwe Pelzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors
- (2015) A. C. Larsen et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- ERKs in Cancer: Friends or Foes?
- (2014) Xavier Deschênes-Simard et al. CANCER RESEARCH
- Epidemiology of cancer-associated venous thrombosis
- (2013) J. F. Timp et al. BLOOD
- Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
- (2011) A. Maraveyas et al. EUROPEAN JOURNAL OF CANCER
- Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer
- (2011) Frederiek F. van Doormaal et al. JOURNAL OF CLINICAL ONCOLOGY
- Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer
- (2011) Laurel A. Menapace et al. THROMBOSIS AND HAEMOSTASIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started